A public health expert explains how GLP-1 drugs have changed the way healthcare providers understand and treat obesity.

Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric ...

GLP-1 drug users are known to have suppressed appetites and a preference for protein-rich foods.

Appetite suppression in people taking GLP-1s could lead to deficiencies in vitamins and nutrients, an expert warns ...

One researcher found patients on the weight loss drugs may not be getting enough essential vitamins and nutrients.

The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...

McDonald’s signaled this week it’s looking to better cater to customers on weight-loss drugs — and the name of the game is ...

Trends shaping GLP-1 landscape include FDA regulatory updates, rapid oral drug adoption, and shifting clinical evidence for diabetes care.

Following functional endoscopic sinus surgery, adults with chronic rhinosinusitis with nasal polyps and obesity had a lower risk for revision surgery if they were prescribed a GLP-1 receptor agonist, ...

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with ...

A Clayman Thyroid Center report aims to clarify FDA safety warnings, finding no evidence that GLP-1 drugs like Ozempic cause common thyroid cancers. Current human data do not show a link between GLP-1 ...

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.